Literature DB >> 25841306

Expression of LATS family proteins in ovarian tumors and its significance.

Bing Xu1, Duoxiang Sun1, Zhihua Wang2, Haiyan Weng2, Dabao Wu1, Xuefen Zhang1, Ying Zhou3, Weiping Hu4.   

Abstract

Epithelial ovarian cancer is composed of a diverse group of tumors that can be derived from the fallopian tube, endometrium, or ovary. In this study, we explored the expression levels of LATS family members in ovarian tumors using normal ovaries, fallopian tubes, and endometrium as controls. Immunohistochemistry studies of LATS1, LATS2, Pax8, and calretinin were performed on normal ovary, fallopian tube, normal endometrium, and ovarian tumor sections. Statistical analyses were conducted using the χ(2) test, Fisher exact test, or Kruskal-Wallis H test. Patient survival was analyzed using the Kaplan-Meier method. LATS1 was expressed in normal ovarian epithelia, endometrium, and fallopian tubes, whereas LATS2 expression was observed in the normal fallopian tubes and endometrium. High expressions of LATS1 and LATS2 in serous cystadenomas gradually decreased in borderline cystadenomas and carcinomas, respectively. However, an opposite expression pattern was observed in mucinous tumors. Low expressions of LATS1 and LATS2 were also detected in clear cell carcinoma. Both LATS1 and LATS2 expression levels significantly correlated with recurrence and stage; LATS1 levels were also related with tumor grades in serous carcinoma. However, univariate and multivariate Cox regression analyses revealed that high expression of LATS1 was associated with better prognosis in patients with serous carcinoma. Both LATS1 and LATS2 were not related with the clinical variables in mucinous and clear cell carcinoma. LATS1 expression levels might be a valuable survival indicator in ovarian serous carcinoma.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clear cell carcinoma; LATS1; LATS2; Ovarian mucinous tumors; Ovarian serous tumors

Mesh:

Substances:

Year:  2015        PMID: 25841306     DOI: 10.1016/j.humpath.2015.02.012

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  16 in total

1.  The clinical significance and biological function of large tumour suppressor 2 in hepatocellular carcinoma.

Authors:  Rong Liang; Yan Lin; Chun-Ling Yuan; Zhi-Hui Liu; Yong-Qiang Li; Xiao-Ling Luo; Jia-Zhou Ye; Hai-Hong Ye
Journal:  Cell Prolif       Date:  2017-03-01       Impact factor: 6.831

2.  RETRACTED ARTICLE: The novel long non-coding RNA LATS2-AS1-001 inhibits gastric cancer progression by regulating the LATS2/YAP1 signaling pathway via binding to EZH2.

Authors:  Dan Sun; Ying Wang; Huan Wang; Yan Xin
Journal:  Cancer Cell Int       Date:  2020-05-29       Impact factor: 6.429

3.  LATS1 Regulates Mixed-Lineage Kinase 3 (MLK3) Subcellular Localization and MLK3-Mediated Invasion in Ovarian Epithelial Cells.

Authors:  Srimathi Kasturirangan; Batool Mehdi; Deborah N Chadee
Journal:  Mol Cell Biol       Date:  2021-06-23       Impact factor: 4.272

4.  Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.

Authors:  Pamela M J McLaughlin; Maximilian Klar; Tibor A Zwimpfer; Gilles Dutilh; Marcus Vetter; Christian Marth; Andreas du Bois; Carmen Schade-Brittinger; Alexander Reuss; Claudine Bommer; Christian Kurzeder; Viola Heinzelmann-Schwarz
Journal:  BMC Cancer       Date:  2022-05-06       Impact factor: 4.638

5.  Loss of large tumor suppressor 1 promotes growth and metastasis of gastric cancer cells through upregulation of the YAP signaling.

Authors:  Jing Zhang; Ge Wang; Shao-Jun Chu; Jin-Shui Zhu; Rui Zhang; Wen-Wen Lu; Li-Qiong Xia; Yun-Min Lu; Wei Da; Qun Sun
Journal:  Oncotarget       Date:  2016-03-29

6.  LATS1 suppresses proliferation and invasion of cervical cancer.

Authors:  Jihong Deng; Wen Zhang; Shuangyue Liu; Hongmei An; Lu Tan; Lisha Ma
Journal:  Mol Med Rep       Date:  2017-02-08       Impact factor: 2.952

Review 7.  The Cross-Talk Between the TNF-α and RASSF-Hippo Signalling Pathways.

Authors:  Delvac Oceandy; Bella Amanda; Faisal Yusuf Ashari; Zakiyatul Faizah; M Aminudin Azis; Nicholas Stafford
Journal:  Int J Mol Sci       Date:  2019-05-11       Impact factor: 5.923

8.  miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2.

Authors:  Zeinab Mohamed; Mohamed Kamel Hassan; Safwat Okasha; Takashi Mitamura; Sarah Keshk; Yusuke Konno; Tatsuya Kato; Sherif F El-Khamisy; Yusuke Ohba; Hidemichi Watari
Journal:  Oncotarget       Date:  2018-07-10

9.  LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state.

Authors:  Noa Furth; Ioannis S Pateras; Ron Rotkopf; Vassiliki Vlachou; Irina Rivkin; Ina Schmitt; Deborah Bakaev; Anat Gershoni; Elena Ainbinder; Dena Leshkowitz; Randy L Johnson; Vassilis G Gorgoulis; Moshe Oren; Yael Aylon
Journal:  Life Sci Alliance       Date:  2018-10-30

Review 10.  Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature.

Authors:  Anello Marcello Poma; Liborio Torregrossa; Rossella Bruno; Fulvio Basolo; Gabriella Fontanini
Journal:  Sci Rep       Date:  2018-07-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.